Influential Analyst Rating Changes: DURECT Corporation (DRRX), Syros Pharmaceuticals, Inc. (SYRS)

DURECT Corporation (NASDAQ:DRRX) tinted gains of +0.02% (0 points) to US$0.84. The volume of 0.2 Million shares climbed down over an trading activity of 285.92 Million shares. EPS ratio determined by looking at last 12 month figures is -0.06. Over the same time span, the stock marked US$2.55 as its best level and the lowest price reached was US$0.79. The corporation has a market cap of US$144.3 Million.

DURECT Corporation (NASDAQ:DRRX)’s earnings per share has been growing at a -16.4 percent rate over the past 5 year when average revenue increase was noted as -1.5 percent. The return on equity ratio or ROE stands at -36.9 percent while most common profitability ratio return on investment (ROI) was -5.4 percent. The company’s institutional ownership is monitored at 48.7 percent. The company’s net profit margin has achieved the current level of -28.4 percent and possesses 87.7 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 2.5. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) is worth US$243.18 Million and has recently fallen -6.79% to US$7. The latest exchange of 0.15 Million shares is below its average trading activity of 122.62 Million shares. The day began at US$7.42 but the price moved to US$6.85 at one point during the trading and finally capitulating to a session high of US$7.57. The stock tapped a 52-week high of US$15.6 while the mean 12-month price target for the shares is US$20.33.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.48, and a price to sales ratio of 202.65. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 75.9%, it carries an earnings per share ratio of -1.95.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.86.